Eli Lilly Unveils $15 Billion Share Repurchase and Continuous Dividend Growth
Eli Lilly and Company has made headlines with the announcement of a robust $15 billion share repurchase program, approved today by the board of directors. This move signifies its strong growth prospects and commitment to returning value to shareholders. The new program follows the successful completion of a previous $5 billion share repurchase scheme which concluded in the fourth quarter of 2024.
As Lilly positions itself for further expansion, the board also declared a 15% increase in its quarterly dividend—marking the seventh consecutive year of growth. For the first quarter of 2025, shareholders can expect a dividend of $1.50 per share, payable on March 10, 2025, to those recorded by February 14, 2025.
"As Lilly enters a period of rapid growth, our capital allocation priorities continue to align with our strategic goals. We remain focused on nurturing new breakthroughs, boosting our manufacturing capacity, and furthering our research and development efforts," stated Lucas Montarce, Lilly's Executive Vice President and Chief Financial Officer. Montarce highlighted that while the company aims to enhance innovative capabilities, it is also committed to increasing shareholder returns, forecasting the execution of its share repurchase program over the next three years.
The share repurchase approach allows flexibility in execution, enabling management to opt for various purchasing methods, including open market transactions, accelerated repurchases, or privately negotiated arrangements. Notably, there is no set time frame for this program, as it can be paused or called off at any given moment.
Eli Lilly has a storied legacy of innovation spanning nearly 150 years, driven by their mission to transform scientific advancements into effective medicines. They cater to numerous global health challenges, including diabetes management, obesity treatment, Alzheimer's care, and tackling significant immune system disorders and complex cancers. The company emphasizes not only their advancements in clinical research but also their commitment to inclusivity and affordability in medicine access.
Investors and analysts will keenly watch how Lilly executes this repurchase program over the forthcoming years, evaluating its impact on stock performance and shareholder value. With the backing of the latest financial measures, Lilly is poised to navigate the competitive landscape of pharmaceuticals while securing its status as a dominant player in the industry.
As Lilly positions itself for further expansion, the board also declared a 15% increase in its quarterly dividend—marking the seventh consecutive year of growth. For the first quarter of 2025, shareholders can expect a dividend of $1.50 per share, payable on March 10, 2025, to those recorded by February 14, 2025.
"As Lilly enters a period of rapid growth, our capital allocation priorities continue to align with our strategic goals. We remain focused on nurturing new breakthroughs, boosting our manufacturing capacity, and furthering our research and development efforts," stated Lucas Montarce, Lilly's Executive Vice President and Chief Financial Officer. Montarce highlighted that while the company aims to enhance innovative capabilities, it is also committed to increasing shareholder returns, forecasting the execution of its share repurchase program over the next three years.
The share repurchase approach allows flexibility in execution, enabling management to opt for various purchasing methods, including open market transactions, accelerated repurchases, or privately negotiated arrangements. Notably, there is no set time frame for this program, as it can be paused or called off at any given moment.
Eli Lilly has a storied legacy of innovation spanning nearly 150 years, driven by their mission to transform scientific advancements into effective medicines. They cater to numerous global health challenges, including diabetes management, obesity treatment, Alzheimer's care, and tackling significant immune system disorders and complex cancers. The company emphasizes not only their advancements in clinical research but also their commitment to inclusivity and affordability in medicine access.
Investors and analysts will keenly watch how Lilly executes this repurchase program over the forthcoming years, evaluating its impact on stock performance and shareholder value. With the backing of the latest financial measures, Lilly is poised to navigate the competitive landscape of pharmaceuticals while securing its status as a dominant player in the industry.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.